封面
市場調查報告書
商品編碼
1243833

狼瘡治療藥的全球市場

Lupus Therapeutics

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

狼瘡治療藥的全球市場2030年前將達到67億美元

在COVID-19後改變的商務環境中,2022年34億美元的狼瘡治療藥的全球市場,2030年前將達到67億美元的規模,在2022年~2030年預計將以年複合成長率8.7%增長。本報告所分析之市場區隔之一的抗發炎劑年複合成長率將記錄8.1%,到分析期間結束時將達到25億美元。考慮疫情後的復甦,腎上腺皮質荷爾蒙劑市場領域今後8年的年複合成長率將修正為8.3%。

美國市場估算為10億美元,中國則將以年複合成長率8.2%增長。

美國的狼瘡治療藥市場在2022年估算為10億美元。作為世界第2大經濟大國的中國,在2022年~2030年年複合成長率預計將為8.2%,2030年前將達到12億美元的市場規模。其他熱門的地區市場有日本和加拿大,在2022年~2030年預計將各以7.9%和7.2%的速度成長。在歐洲市場中,德國以年複合成長率約7.1%成長。

調查對像企業範例

  • ADMA Biologics, Inc.
  • Amgen, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • Biogen, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Kedrion Biopharma, Inc.
  • LFB Group
  • MedImmune, LLC
  • Merck KgaA
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC
  • Takeda Pharmaceuticals Company Ltd.
  • UCB SA

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP13122

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Lupus Therapeutics Market to Reach $6.7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Lupus Therapeutics estimated at US$3.4 Billion in the year 2022, is projected to reach a revised size of US$6.7 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 8.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 8.2% CAGR

The Lupus Therapeutics market in the U.S. is estimated at US$1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Select Competitors (Total 17 Featured) -

  • ADMA Biologics, Inc.
  • Amgen, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • Biogen, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Kedrion Biopharma, Inc.
  • LFB Group
  • MedImmune, LLC
  • Merck KgaA
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC
  • Takeda Pharmaceuticals Company Ltd.
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Lupus Therapeutic - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Lupus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Lupus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Lupus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Immunosuppressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Antimalarial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Antimalarial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for BLyS-Specific Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for BLyS-Specific Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Biologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Biologicals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 25: World Lupus Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • JAPAN
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • CHINA
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: China 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • EUROPE
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Lupus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Lupus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • FRANCE
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: France 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • GERMANY
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: UK 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Lupus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Rest of World Historic Review for Lupus Therapeutics by Drug Class - Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Rest of World 16-Year Perspective for Lupus Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-Inflammatory Drugs, Corticosteroids, Immunosuppressant Drugs, Antimalarial Drugs, BLyS-Specific Inhibitors, Biologicals and Other Drug Classes for the Years 2014, 2023 & 2030

IV. COMPETITION